Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
暂无分享,去创建一个
M. J. Charron | R. Unger | May-yun Wang | Y. Lee | X. Du
[1] O. Ilkayeva,et al. Leptin therapy in insulin-deficient type I diabetes , 2010, Proceedings of the National Academy of Sciences.
[2] R. Wysocki,et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. , 2010, Cell metabolism.
[3] D. Drucker,et al. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. , 2009, Endocrinology.
[4] Byung-Hyun Park,et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin , 2008, Proceedings of the National Academy of Sciences.
[5] C. Everett-Grueter,et al. A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog , 2007, Journal of Pharmacology and Experimental Therapeutics.
[6] A. Tiengo,et al. Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis , 1980, Acta diabetologia latina.
[7] T. Tobe,et al. Changes in plasma glucagon after total pancreatectomy in man , 2007, Gastroenterologia Japonica.
[8] M. J. Charron,et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia , 2006, Diabetologia.
[9] L. Orci,et al. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] D. Moller,et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. , 2004, Diabetes.
[11] N. Porksen,et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.
[12] B. Monia,et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. , 2004, Diabetes.
[13] Ianessa Morantte,et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ , 2003, Nature.
[14] M. Fukuzawa,et al. Peculiar glucagon processing in the intestine is the genesis of the paradoxical rise of serum pancreatic glucagon in patients after total pancreatectomy. , 2003, Hepato-gastroenterology.
[15] J. Holst,et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] S. Djurić,et al. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. , 2002, Current opinion in investigational drugs.
[17] S. Welle,et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. , 2002, American journal of physiology. Endocrinology and metabolism.
[18] K. Petersen,et al. Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans , 2001, Diabetologia.
[19] Carolyn B Levy,et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. , 2000, Diabetes.
[20] A. Cherrington,et al. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. , 1997, The American journal of physiology.
[21] I. Svendsen,et al. Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits , 1996, Diabetes.
[22] L. Bardram,et al. Increased amino acid clearance and urea synthesis in a patient with glucagonoma. , 1990, Gut.
[23] K. Jungermann,et al. Mechanism of the inhibition by insulin of the glucagon-dependent activation of the phosphoenolpyruvate carboxykinase gene in rat hepatocyte cultures. Action on gene transcription, mRNA level and -stability as well as hysteresis effect. , 1990, Biological chemistry Hoppe-Seyler.
[24] J. Fortner,et al. Glucagon Immunoreactivity and Chromatographic Profiles in Pancreatectomized Humans: Paradoxical Response to Oral Glucose , 1986, Diabetes.
[25] L. Orci,et al. Insulin within islets is a physiologic glucagon release inhibitor. , 1984, The Journal of clinical investigation.
[26] M. Granner,et al. Insulin and Glucagon Regulate Cytosolic Phosphoenolpyruvate Carboxykinase (GTP) mRNA in Rat Liver , 1984, Diabetes.
[27] O. Owen,et al. Effects of glucagon on plasma amino acids. , 1984, The Journal of clinical investigation.
[28] V. Hruby,et al. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. , 1982, Science.
[29] L. Orci,et al. Demonstration of Glucagon in the Stomach of Human Fetuses , 1981, Diabetes.
[30] G WhittakerP,et al. 共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .
[31] J. Norton,et al. Amino acid deficiency and the skin rash associated with glucagonoma. , 1979, Annals of internal medicine.
[32] S. Tarui,et al. A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin. , 1979, Diabete & metabolisme.
[33] P. Raskin,et al. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. , 1978, The New England journal of medicine.
[34] M. Vranic,et al. Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs. , 1978, The American journal of physiology.
[35] L. Orci,et al. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. Tsalikian,et al. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. , 1975, The New England journal of medicine.
[37] M. Chou,et al. Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs. , 1975, Endocrinology.
[38] L. Orci,et al. Glucagon: role in the hyperglycemia of diabetes mellitus. , 1975, Science.
[39] L. Orci,et al. THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.
[40] N. Ling,et al. [Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine]. , 1973, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles.
[41] W. A. Müller,et al. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. , 1973, The American journal of medicine.
[42] R. Unger,et al. Studies of the development of diabetic ketosis in the rat. , 1972, Journal of lipid research.
[43] R. Unger,et al. The effects of total starvation upon the levels of circulating glucagon and insulin in man. , 1963, The Journal of clinical investigation.
[44] R. Unger,et al. Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. , 1962, Diabetes.
[45] R. Unger,et al. Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. , 1962, The Journal of clinical investigation.
[46] R. Unger,et al. Glucagon Antibodies and Their Use for Immunoassay for Glucagon.∗ , 1959, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.